Avadel Pharmaceuticals (AVDL) Projected to Post Earnings on Tuesday

Avadel Pharmaceuticals (NASDAQ:AVDL) will likely be posting its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Avadel Pharmaceuticals to post earnings of $0.08 per share for the quarter. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:30 AM ET.

Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its earnings results on Thursday, August 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.02 by $0.08. The company had revenue of $68.13 million for the quarter, compared to the consensus estimate of $60.28 million. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The firm’s revenue for the quarter was up 64.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.14) EPS. On average, analysts expect Avadel Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Avadel Pharmaceuticals Trading Down 0.3%

NASDAQ AVDL traded down $0.06 on Tuesday, hitting $18.87. 221,537 shares of the company were exchanged, compared to its average volume of 1,674,301. The company has a market cap of $1.83 billion, a P/E ratio of -628.83 and a beta of 1.46. Avadel Pharmaceuticals has a 1-year low of $6.38 and a 1-year high of $19.06. The firm has a 50 day moving average of $15.84 and a two-hundred day moving average of $12.14.

Analyst Ratings Changes

AVDL has been the subject of a number of recent research reports. UBS Group downgraded Avadel Pharmaceuticals to a “neutral” rating in a research report on Tuesday, October 28th. Lifesci Capital downgraded shares of Avadel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Zacks Research lowered shares of Avadel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. Leerink Partners reissued a “market perform” rating and issued a $18.50 price objective on shares of Avadel Pharmaceuticals in a research report on Thursday, October 23rd. Finally, HC Wainwright lowered shares of Avadel Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $20.00 price objective on the stock. in a research report on Thursday, October 23rd. One research analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Avadel Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $17.31.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Creative Planning raised its stake in Avadel Pharmaceuticals by 10.0% in the second quarter. Creative Planning now owns 19,376 shares of the company’s stock valued at $171,000 after purchasing an additional 1,759 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Avadel Pharmaceuticals by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 54,885 shares of the company’s stock worth $430,000 after acquiring an additional 2,291 shares during the period. Rhumbline Advisers lifted its stake in shares of Avadel Pharmaceuticals by 3.9% in the second quarter. Rhumbline Advisers now owns 131,978 shares of the company’s stock worth $1,168,000 after acquiring an additional 4,951 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Avadel Pharmaceuticals by 30.8% in the second quarter. BNP Paribas Financial Markets now owns 22,823 shares of the company’s stock worth $202,000 after acquiring an additional 5,372 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Avadel Pharmaceuticals by 217.5% in the second quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company’s stock worth $78,000 after acquiring an additional 6,025 shares during the period. Institutional investors and hedge funds own 69.19% of the company’s stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.